IWWM-12: What are the implications of iStopMM for MM and WM?

During the 12th International Workshop on Waldenstrom's Macroglobulinemia (IWWM-12), the Lymphoma Hub was pleased to speak to Sæmundur Rögnvaldsson, University of Iceland, Reykjavik, IS. We asked about the iStopMM study and the implications of these data for both patients with multiple myeloma (MM) and those with Waldenstrom's macroglobulinemia (WM).

In this interview, Rögnvaldsson discusses his role in the iStopMM (NCT03327597) study, which screens for monoclonal gammopathies (MGUS) to detect early MM and WM. Rögnvaldsson highlights the key findings, including the potential for early diagnosis to reduce disease severity and hospitalizations. Rögnvaldsson also covers the study's long-term goals, including refining follow-up, developing predictive models for progression, and understanding the biological processes behind benign versus malignant conditions. He concludes with a look at how these data could help improve outcomes in both MM and WM through optimized treatment and disease management.

This educational resource was independently supported by BeiGene. All content was developed by SES in collaboration with an expert steering committee; funders were allowed no influence on the content of this resource